LTUS — Lotus Pharmaceuticals Share Price
Last trade - 00:00- $18.86m
- $24.12m
- $72.70m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.19 | ||
| Price to Tang. Book | 0.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.27 | ||
| EV to EBITDA | 8.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.76% | ||
| Return on Equity | 1.81% | ||
| Operating Margin | 1.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2006 | 2007 | 2008 | 2009 | 2010 | 2011E | 2012E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 36.21 | 56.87 | 73.8 | 56.48 | 72.7 | n/a | n/a | 31.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +124.55 | +101.09 | +28.91 | +35.99 | +8.02 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.
Directors
- Zhongyi Liu CEO (50)
- Yan Zeng CFO (53)
- Xing Shen VPR (40)
- Lu Jun DRC (31)
- Fan Lijun IND (42)
- Li Zhaohui IND (42)
- Last Annual
- December 31st, 2010
- Last Interim
- September 30th, 2011
- Incorporated
- January 28th, 2004
- Public Since
- May 15th, 2012
- No. of Shareholders
- 58
- No. of Employees
- 233
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 2,694,515,543
- Address
- 16 Cheng Zhuang Road, Feng Tai District, BEIJING, 100071
- Web
- http://www.lotuspharma.com
- Phone
- +86 1063899868
- Auditors
- Friedman LLP
Similar to LTUS
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:13 UTC, shares in Lotus Pharmaceuticals are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Lotus Pharmaceuticals last closed at $0.01 and the price had moved by -36.36% over the past 365 days. In terms of relative price strength the Lotus Pharmaceuticals share price has underperformed the S&P500 Index by -43.86% over the past year.
There is no consensus recommendation for this security.
Lotus Pharmaceuticals does not currently pay a dividend.
Lotus Pharmaceuticals does not currently pay a dividend.
Lotus Pharmaceuticals does not currently pay a dividend.
To buy shares in Lotus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Lotus Pharmaceuticals had a market capitalisation of $18.86m.
Here are the trading details for Lotus Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: LTUS
Based on an overall assessment of its quality, value and momentum Lotus Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +9.72%.
As of the last closing price of $0.01, shares in Lotus Pharmaceuticals were trading -45.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lotus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lotus Pharmaceuticals' management team is headed by:
- Zhongyi Liu - CEO
- Yan Zeng - CFO
- Xing Shen - VPR
- Lu Jun - DRC
- Fan Lijun - IND
- Li Zhaohui - IND